Last reviewed · How we verify
NCT06147648
Early Conversion of Prolonged-release Tacrolimus in Liver Transplantation.
Phase 4 trial testing Tacrolimus Sustained-release Capsules in Liver Transplantation in 352 participants. Not yet recruiting.
30 July 2025
Quick facts
| Lead sponsor | Beijing Tsinghua Chang Gung Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 352 |
| Start date | 1 December 2023 |
| Primary completion | 30 July 2025 |
| Estimated completion | 30 July 2026 |
Drugs / interventions tested
- Tacrolimus Sustained-release Capsules — full drug profile →
Conditions studied
- Liver Transplantation — all drugs for Liver Transplantation →
Sponsor
Beijing Tsinghua Chang Gung Hospital
Who can join
18 and older, any sex, with Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tacrolimus is a commonly used immunosuppressant after liver transplantation. A once-daily administration of prolonged-release tacrolimus has been found to improve patient compliance and offer good efficacy and safety. Moreover, there is evidence that this prolonged-release formulation mitigates renal impairment and metabolic syndrome in transplant recipients. Foreign studies have confirmed that it is safe and feasible for liver transplant recipients to switch from immediate-release tacrolimus to prolonged-release tacrolimus during the stable period. At the same time, patients with early conversion are more likely to benefit in terms of graft survival and renal function recovery, and the proportion of drug conversion needs to be further explored. This study aims to assess the efficacy and safety of switching from immediate-release tacrolimus to prolonged-release tacrolimus three months after liver transplantation. Furthermore, it seeks to investigate the impact of this conversion on indicators such as liver function, kidney function, metabolic disease incidence, and infection incidence in patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06147648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tacrolimus Sustained-release Capsules
Trials testing the same drug.
- NCT06183892 — Prospective, Multicenter Clinical Study of Prolonged-release Tacrolimus in Stable Pediatric Liver Transplant Recipients · NA · recruiting
Other recruiting trials for Liver Transplantation
Currently open trials in the same condition.
- NCT07157631 — Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial · NA · recruiting
- NCT07123740 — Comparison of the Postoperative Analgesic Effects of ITM and Bi-level ESPB in Liver Transplantation Donors · NA · recruiting
- NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting
- NCT06868589 — Reducing Pain With Methadone and Ketamine in Liver Transplant · Phase 4 · active not recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
Other Beijing Tsinghua Chang Gung Hospital trials
Trials by the same sponsor.
- NCT07123675 — AI-Assisted Blood Pressure Control During Anesthesia · NA · not yet recruiting
- NCT07152496 — Host-Microbe Interactions in Biliary Dilatation · not yet recruiting
- NCT07330271 — PTC-Guided Therapy for Peritoneal Mesothelioma · NA · recruiting
- NCT07328737 — One vs Three HIPEC Cycles After CRS for Pseudomyxoma Peritonei · NA · recruiting
- NCT07044947 — Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC） · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06147648 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tsinghua Chang Gung Hospital
- Last refreshed: 27 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing